OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ghia on Lack of OS Advantage With Acalabrutinib Per ASCEND Trial in CLL

August 10th 2020

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

August 10th 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10th 2020

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Recent Advances in Melanoma

August 10th 2020

Grace Cherry, RN, ​MSN, NP, discusses ​recent advances in melanoma. 

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

August 10th 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Ahmed on the Role of Multidisciplinary Care in Breast Cancer Brain Metastases

August 10th 2020

Kamran A. Ahmed, MD, discusses the role of multidisciplinary care in breast cancer–related brain metastases.

Dr. VanderWalde on Personalizing Therapy in Rectal Cancer

August 10th 2020

Noam VanderWalde, MD, MS, discusses the push toward personalizing therapy in rectal cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC

August 7th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC

August 7th 2020

Jennifer L. Atlas, MD, discusses the rationale for using cemiplimab-rwlc as a first intervention for patients with locally advanced cutaneous squamous cell carcinoma.

Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

August 7th 2020

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma

August 7th 2020

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma. 

Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera

August 7th 2020

Ronald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.

Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC

August 7th 2020

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

August 7th 2020

Sara A. Hurvitz, MD, discusses the lack of predictive biomarkers in HER2-positive breast cancer.

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma

August 6th 2020

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases

August 6th 2020

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic

August 6th 2020

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma

August 6th 2020

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

NEXT PAGE
PREVIOUS PAGE